SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) August 5, 1998
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission FileNumber) (IRS Employer
of incorporation Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
<PAGE>
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced marketing
plans for the Diasensor 1000. To penetrate
international markets by aggressive Internet marketing,
licensing the Diasensor technology, entering into joint
venture agreements to market and/or manufacture the
sensor, and by establishing exclusive distributors.
Initial focus will be on the 15-member European Union
with a market of 30 million people with diabetes. The
Diasensor's market entry price will be US $9,000. In
addition, Diasense will proceed with other markets
outside the EU with large diabetic populations where
the CE Mark is not required but is looked to for
medical devices.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired
Not Applicable.
(b) Pro Forma Financial Information
Not Applicable.
(c) Exhibits - Press Release.
<PAGE>
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: August 5, 1998
<PAGE>
BIOCONTROL TECHNOLOGY, INC.
2275 Swallow Hill Road,
Building 2500
Pgh PA 15220
PRESS RELEASE
For More Information, Call:
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.279.9455 phone
1.412.279.9690 fax 1.412.279.9447 fax
BIOCONTROL DIASENSE SUBSIDIARY TO MARKET DIASENSOR ON THE INTERNET
Pittsburgh, PA -August 5,1998 -Biocontrol Technology, Inc.
(Nasdaq:BICO) subsidiary Diasense, Inc. today announced marketing
plans for the Diasensor r 1000, the world's first noninvasive
glucose sensor, which recently received European marketing
approval. Diasense plans to penetrate international markets by
aggressive Internet marketing, licensing the Diasensor
technology, entering into joint venture agreements to market
and/or manufacture the sensor, and by establishing exclusive
distributors. Initial focus will be on the 15-member European
Union (EU), with a market of 30 million people with diabetes.
The Diasensor's market entry price will be US $9,000.
In addition, Diasense will proceed with other markets
outside the EU with large diabetic populations where the CE Mark
is not required but is looked to for medical devices. For
example, India, Saudi Arabia, United Arab Emirates, and Pakistan
combined account for approximately 26,500,000 diabetics.
Because the Diasensor is the first noninvasive glucose
sensor to ever be made commercially available to the diabetic
population, Diasense will also work to educate and establish a
network of clinicians, health care professionals, and diabetic
associations in each country.
Biocontrol Technology, Inc. (www.bico.com) has its corporat
offices in Pittsburgh, PA and is involved in the development and
manufacture of biomedical devices and environmental products.
Also located in Pittsburgh, PA, Diasense is a subsidiary of
Biocontrol Technology and owns the patent, marketing and
distribution rights to the sensor. Biocontrol has the exclusive
rights to the research and development and manufacturing of the
Sensor.
This press release contains forward looking statements and
shareholders and potential investors are
cautioned that such statements are predictions and actual
events or results may vary significantly.
